Improvement of platelet dysfunction in chronic myelogenous leukemia following treatment with imatinib: A case report

被引:6
|
作者
Shimabukuro-Vornhagen A. [1 ]
Rothe A. [1 ]
Nogova L. [1 ]
Kochanek M. [1 ]
Scheid C. [1 ]
Von Bergwelt-Baildon M. [1 ]
机构
[1] Department i of Internal Medicine, University Hospital Cologne, D-50924 Köln
关键词
Imatinib; Chronic Myeloid Leukemia; International Normalize Ratio; Dasatinib; Fresh Freeze Plasma;
D O I
10.1186/1752-1947-5-215
中图分类号
学科分类号
摘要
Introduction. In patients with chronic myeloid leukemia, tyrosine kinase inhibitors suppress the BCR-ABL+ clone and often induce complete molecular remissions. Megakaryocytes in such patients have been shown to be derived from the BCR-ABL+ clone, and abnormal platelet function is frequent in chronic myeloid leukemia. However, little is known about the influence of modern targeted therapy on chronic myeloid leukemia-associated platelet disorders. Case presentation. We report the case of a massive hemorrhage in a 32-year-old Caucasian man caused by chronic myeloid leukemia-associated platelet dysfunction, which improved after treatment with imatinib. Conclusion: This report demonstrates that platelet dysfunction and bleeding disorder in BCR-ABL+ chronic myeloid leukemia can successfully be treated with imatinib. We suggest the monitoring of platelet function in future studies using imatinib to treat patients with chronic myeloid leukemia. © 2011 Shimabukuro-Vornhagen et al; licensee BioMed Central Ltd.
引用
收藏
相关论文
共 50 条